Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma

home / insights / optimizing-treatment-strategies-in-r-r-hepatocellular-carcinoma
HCC Etiologic Risk Factors and Global Prevalence

EP. 1: HCC Etiologic Risk Factors and Global Prevalence

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
HCC Global Screening Programs for At-Risk Populations

EP. 2: HCC Global Screening Programs for At-Risk Populations

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
The Evolving Role of Medical Oncologists and Hepatologists

EP. 3: The Evolving Role of Medical Oncologists and Hepatologists

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
HCC Diagnosis and Prognosis

EP. 4: HCC Diagnosis and Prognosis

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
Transitioning From Locoregional to Systemic Therapy

EP. 5: Transitioning From Locoregional to Systemic Therapy

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
HCC Treatment Algorithm: Asia and Europe

EP. 6: HCC Treatment Algorithm: Asia and Europe

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
Frontline Decision Factors for Metastatic Disease

EP. 7: Frontline Decision Factors for Metastatic Disease

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
Phase 3 IMbrave150 Trial

EP. 8: Phase 3 IMbrave150 Trial

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
Frontline Therapy: Promising I/O Combinations

EP. 9: Frontline Therapy: Promising I/O Combinations

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
Frontline I/O: Clinical Trial Overviews

EP. 10: Frontline I/O: Clinical Trial Overviews

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
R/R HCC: Second-Line Options

EP. 11: R/R HCC: Second-Line Options

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
Second-Line Sequencing After IMbrave150 Regimen

EP. 12: Second-Line Sequencing After IMbrave150 Regimen

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
Second-Line Therapy: Monoclonal Antibody

EP. 13: Second-Line Therapy: Monoclonal Antibody

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
REACH and REACH2 Trial Overview

EP. 14: REACH and REACH2 Trial Overview

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
I/O Second-Line Treatment

EP. 15: I/O Second-Line Treatment

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
Metastatic HCC Unmet Needs

EP. 16: Metastatic HCC Unmet Needs

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020
Emerging Therapies for HCC Management

EP. 17: Emerging Therapies for HCC Management

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020